奥氮平与齐拉西酮治疗精神分裂症对照研究

目的 探讨奥氮平与齐拉西酮治疗精神分裂症的临床疗效及安全性.方法将80例精神分裂症患者随机分为两组,每组40例,研究组口服奥氮平治疗,对照组口服齐拉西酮治疗,观察8周.于治疗前后采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降(P<0.01...

A control study of olanzapine vs.ziprasidone in the treatment of schizophrenia

Objective To explore the clinical efficacy and safety of olanzapine vs. ziprasidone in the treatment of schizophrenia. Methods Eighty schizophrenics were randomly divided into two groups of 40 patients each, research group took orally olanzapine and control group did ziprasidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before and after treatment. Results The PANSS total and each factor scores of both groups lowered more significantly after treatment compared with pre- treatment （P〈O. 01）, but negatice symptom score lowered more significantly in the research than in the control group （P〈0.01） ; at the end of the 8th week, obvious and total effective rates were 86.49% and 97. 300/oo in the research and 84.21% and 94.74% in the control group, respectively, which showed no sig- nificant differences （x^2=0. 744,P〉0.05）. Adverse reactions were mainly weight gain in the research and headache, dizziness, QT interval prolongation, tremor etc. The incidences of headache, dizziness, QT interval prolongation were significantly lower and that of weight gain higher in the research than in the con trol group, all differences had significance （P〈0.05 or 0.01）. Conclusion Both olanzapine and ziprasidone have an significant efficacy in the treatment of schizophrenia, their total efficacy are equivalent, safety high and compliance good, but the former has the advantage of the latter in improving negative symptoms.